|
Match
|
Document |
Document Title |
|
|
7297535 |
Use of the human LRP/MVP promotor for a vector that can be induced by therapy
Embodiments of the invention relate to a vector system that allows one to induce expression of therapeutically relevant genes in mammalian cells. Such a vector system may be useful for medicine and...
|
|
|
7297475 |
Medicament injection kit and medicament injection method
A medicament injection kit, for use in occluding a renal artery and a renal vein in a kidney and injecting a therapeutic medicament into the kidney so as to pressurize the kidney, includes: an...
|
|
|
7297341 |
Chlamydia antigens and corresponding DNA fragments and uses thereof
The present invention provides purified and isolated polynucleotide molecules that encode Chlamydia polypeptides which can be used in methods to prevent, treat, and diagnose Chlamydia ...
|
|
|
7294505 |
Stable episomal vectors
The present invention provides a vector system which can be stably translocated from the cytoplasm of a cell to the nucleus where it is a stable nuclear episomal vector. A basic vector system...
|
|
|
7294496 |
Cloned human lysophospholipase
A cloned of a human brain lysophospholipid-specific lysophospholipase enzyme molecule, its potential use for treatment of a host of diseases and method of inactivation are disclosed. Also disclosed...
|
|
|
7294338 |
Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies
Disclosed is an immunological or vaccine composition that includes at least one plasmid that contains and expresses in vivo in host canine cells a nucleic acid molecule that encodes an antigen of a...
|
|
|
7291605 |
Methods of treating various cancers using melanoma differentiation associated protein-7
This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under...
|
|
|
7291604 |
Methods of treating restenosis
Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent...
|
|
|
7288531 |
Potent inhibition of influenza virus by specifically designed short interfering RNA
This patent application discloses siRNA sequences against the constant region of the influenza virus nucleoprotein gene comprising:
Sense strand: 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ (SEQ ID NO: 1)...
|
|
|
7288530 |
Antisense modulation of survivin expression
Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides,...
|
|
|
7288529 |
ALK protein tyrosine kinase, cells and methods embodying and using same
The present invention provides for a transgenic animal model that constitutively expresses a protein encoded by the NPM-ALK gene in lymphoid tissue, and exhibits enhanced and accelerated...
|
|
|
7285542 |
Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene...
|
|
|
7285541 |
Treatment of melanoma by reduction in clusterin levels
Treatment of melanoma is achieved through reduction in the effective amount of clusterin in melanoma cells of in a mammalian subject, preferably a human. A therapeutic agent effective to reduce the...
|
|
|
7285540 |
Medicament comprising HGF gene
The present invention relates to a medicament comprising a HGF gene. The medicament of the present invention may be topically applied to the target organs so that the effects can be selectively...
|
|
|
7285539 |
Activation of HCV-specific T cells
The invention provides a method of activating hepatitis C virus (HCV)-specific T cells, including CD4 + and CD8 + T cells. HCV-specific T cells are activated using fusion proteins comprising HCV...
|
|
|
7285538 |
Gene repair involving in vivo excision of targeting DNA
Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in...
|
|
|
7285537 |
Oligonucleotide therapeutic agent and methods of making same
For use in controlling biologic functions in an organism, a stabilized oligonucleotide, preferably in a phosphotriester form, having a base sequence substantially complementary to a portion of...
|
|
|
7285527 |
Tumor radiosensitization using gene therapy
The invention provides a method of radiosensitizing a tumor in a subject by contacting the tumor with a cytokine or a nucleic acid molecule encoding a cytokine. The invention also provides a method...
|
|
|
7285288 |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The...
|
|
|
7282490 |
Osteopontin-related compositions and methods
This invention provides a method for reducing the amount of osteopontin in an osteopontin-expressing cell comprising introducing into the cell a nucleic acid which specifically inhibits osteopontin...
|
|
|
7282489 |
Compositions and methods for performing reverse gene therapy
The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an...
|
|
|
7282488 |
Genetic engineering of vascular grafts to resist disease
Disclosed are methods for treating a vascular graft that include introducing an effective amount of at least one nucleic acid encoding at least one agent that increases activated protein C (APC),...
|
|
|
7282200 |
Mixed-cell gene therapy
The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a...
|
|
|
7279464 |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40...
|
|
|
7279463 |
Triple-helix forming oligonucleotides for targeted mutagenesis
A high affinity, triplex-forming oligonucleotide and methods for use thereof wherein an oligonucleotide is used to form a triple-stranded nucleic acid molecule with a specific DNA segment of a...
|
|
|
7279462 |
Somatic transgene immunization and related methods
The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic...
|
|
|
7279171 |
Vaccines for Chlamydia psittaci infections
Vaccine compositions protective against Chlamydia psittaci infections in animals, including but not limited to humans and avian species, comprising an immunogenic amount of a C. psittaci major...
|
|
|
7276490 |
Medicinal compositions containing prostacylin synthase gene
The present invention relates to: pharmaceutical compositions for inducing apoptosis in cells, the pharmaceutical compositions comprising a prostacyclin synthase gene as an active ingredient;...
|
|
|
7276489 |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods...
|
|
|
7276488 |
Vector system
The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject,...
|
|
|
7276357 |
Compositions and methods for enhancing polynucleotide amplification reactions
Compositions and methods for enhancing PCR and other polynucleotide replication reactions are disclosed. These comprise the addition of low molecular weight organic amides, sulfones or sulfoxides...
|
|
|
7276333 |
Viral infection inhibitor targeting integrase N-terminal domain
The object of the present invention is to provide a screening method of a new integrase inhibitor being able to inhibit an HIV infection before the reverse transcription step and having a...
|
|
|
7276234 |
Method of acquiring immunological tolerance
The aim of the present invention is to provide a method of acquiring immunological tolerance to a foreign DNA or its expression product whereby the foreign DNA such as a vector carrying a foreign...
|
|
|
7273855 |
Use of prohibitin RNA in treatment of cancer
It has now been found that the introduction of single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3′UTR, into tumors leads to...
|
|
|
7273854 |
Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative disorders
The present invention relates to pharmaceutical compositions that act on the p53 protein or its gene and methods of use for the treatment of neurodegenerative diseases.
|
|
|
7273709 |
Detection of sarcocystis neurona
A gene encoding a 29 kilodalton protein found on the surface of merozoite stage S. neurona has been cloned and sequenced. The protein encoded by this gene, termed SnSAG-1, is an immunodominant...
|
|
|
7271156 |
Immunostimulatory nucleic acids
The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T...
|
|
|
7268121 |
Suppression of nuclear factor-κB dependent processes using oligonucleotides
Antisense oligonucleotides which hybridize with nuclear factor-κB(NF-κB) mRNA and methods of using these oligonucleotides.
|
|
|
7268120 |
Methods for treating cancer using cytokine-expressing polynucleotides
The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon ω and one or...
|
|
|
7267977 |
Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer
The expression and subcellular localization of peripheral-type benzodiazepine receptors (PBR) is shown in this application to correlate with the metastatic potential of cells, and increased cell...
|
|
|
7265095 |
Monoclonal antibody 3F1H10 neutralising VHSV (viral haemorrhagic septicaemia virus)
The present invention relates to a non-infectious nucleic acid (RNA and DNA) construct constructed to express a recombinant antibody or antibody fragment in a host cell. The antibody molecule...
|
|
|
7262175 |
Synthetic oligonucleotides as inducers of erythroid differentiation
The invention refers to a synthetic double-stranded oligonucleotide having a length comprised between 10 and 50 bases and a nucleic acid sequence selected from the group consisting of: (a)...
|
|
|
7262174 |
Treatment for wounds
It has been discovered that increasing telomerase activity in cells surrounding a wound has a variety of effects that enhance wound healing. Replication capacity is enhanced, and the mobility of...
|
|
|
7262173 |
Chemosensitizing with liposomes containing oligonucleotides
The invention relates to the use of oligonucleotide containing cationic liposomal formulations to enhance the efficacy of chemotherapy and/or radiotherapy, particularly as a means to sensitize...
|
|
|
7259151 |
AAV virions with decreased immunoreactivity and uses therefor
Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate...
|
|
|
7259150 |
Modulation of apolipoprotein (a) expression
Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a)....
|
|
|
7259149 |
Methods for treating or preventing angiogenesis-dependent symptoms
A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present...
|
|
|
7256182 |
Gene delivery compositions and methods
The present provides methods and compositions that enable effective delivery of nucleic acids to desired cells, including to a solid organ such as a mammalian heart. The methods and compositions...
|
|
|
7256181 |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
Methods and pharmaceutical compositions for modifying cells of a mammalian recipient with DNA encoding a secreted protein such as human interferon in situ are provided. The methods include forming...
|
|
|
7256180 |
Compositions and methods for inducing activation of dendritic cells
Compositions induce the activation of dendritic cells comprising a polynucleotide, such as viruses, RNA, DNA, plasmid DNA, or derivatives thereof and at least one block copolymer of alkylethers....
|